Silence Therapeutics plc Research And Development Expense
Silence Therapeutics plc (SLNCF) reported Research And Development Expense of GBP 44.02 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-03-13.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2024-03-13
| Period end | Research And Development Expense 12 month |
|---|---|
| 2023-12-31 | 44.02M GBP 20-F · filed 2024-03-13 |
| 2022-12-31 | 35.60M GBP 20-F · filed 2024-03-13 |
| 2021-12-31 | 30.77M GBP 20-F · filed 2024-03-13 |
| 2020-12-31 | 20.21M GBP 20-F · filed 2023-03-15 |
| 2019-12-31 | 13.34M GBP 20-F · filed 2022-03-17 |
| 2018-12-31 | 9.74M GBP 20-F/A · filed 2021-04-29 |